Fas ligand

Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, May 4, 2023
COPD, Fucose, CDG, John Avalos, Decoy receptor 3, Birth, Research, Lung, Fas ligand, Net, BTLA, Phase 10, NEA, LAD, Patient, Mab, Asthma, Cytokine, Therapy, Glycosylation, IND, TL1A, Skin, Safety, Inflammation, Pharmaceutical industry, Vaccine

Disclosed cash of approximately $16.7 million as of March 31, 2023

Key Points: 
  • Disclosed cash of approximately $16.7 million as of March 31, 2023
    WAYNE, Pa. and ROCKVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the first quarter of 2023.
  • NEA: Avalo has completed enrollment of the Phase 2 PEAK trial evaluating the safety and efficacy of AVTX-002 in 91 patients with NEA.
  • First Quarter 2023 Financial Update:
    Avalo had $16.7 million in cash and cash equivalents as of March 31, 2023, representing a $3.5 million increase compared to December 31, 2022.
  • The net loss and net loss per share for the three months ended March 31, 2023 was largely driven by operating expenses.

Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids

Retrieved on: 
Wednesday, April 26, 2023
Fas, TNF, CD95, Fas receptor, Survival, Research, Hematological Cancer Research Investment and Education Act, CAR, Apoptosis, Chimera, Neoplasm, Fas ligand, Vaccine

One such inhibitory factor is Fas ligand (FasL), which binds to the Fas receptor (CD95) on the surface of an activated T cell and triggers the CAR T cell to die by apoptosis.

Key Points: 
  • One such inhibitory factor is Fas ligand (FasL), which binds to the Fas receptor (CD95) on the surface of an activated T cell and triggers the CAR T cell to die by apoptosis.
  • The research group at Autolus tested several Fas chimeras which consist of the extracellular domain of Fas fused to the intracellular domain from different TNF receptor superfamily members.
  • Expression of these chimeras in a CAR T cell not only blocks apoptosis triggered by FasL, but results in co-stimulation, which promotes CAR T cell survival and proliferation.
  • These data support the potential of this Fas-CD40 chimera to render T cell therapies resistant to FasL-mediated cell death and improve their effectiveness against solid tumors.

Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

Retrieved on: 
Tuesday, January 17, 2023
Hospital, NEA, Therapy, Cytokine, TL1A, Tablet, Safety, Inflammation, Skin, Lung, PEAK, Fas ligand, Patient, Clinical trial, Asthma, Decoy receptor 3, BTLA, Pharmaceutical industry

WAYNE, Pa. and ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that it completed enrollment of the 80 patients targeted for the Phase 2 PEAK Trial evaluating AVTX-002 (anti-LIGHT mAb) in patients with Non-Eosinophilic Asthma (NEA).

Key Points: 
  • WAYNE, Pa. and ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that it completed enrollment of the 80 patients targeted for the Phase 2 PEAK Trial evaluating AVTX-002 (anti-LIGHT mAb) in patients with Non-Eosinophilic Asthma (NEA).
  • Avalo will allow additional patients currently in the run-in period to complete enrollment.
  • Topline data from the clinical trial are expected to be released in the second quarter of 2023.
  • “We are very excited to have completed target enrollment in our Phase 2 PEAK Trial in patients with NEA.

iTolerance and LyGenesis Announce a Joint Research Collaboration to Regrow Functioning, Ectopic Livers Without the Need for Immune Suppression

Retrieved on: 
Thursday, June 30, 2022
Model for End-Stage Liver Disease, FDA, Liver failure, Patient, Ageing, Protein, B cell, Research, CRISPR, Immunosuppression, Pancreas, Company, Metabolism, Hormone, SA, Hepatocyte, Bioreactor, Kidney, Lymph, Good manufacturing practice, Regenerative medicine, Type 1, Technology, Fas ligand, Blood, Entrepreneurship, Animal, Immune tolerance, Time, Organoid, Pharmaceutical industry, Vaccine

The joint research collaboration has generated in vitro data with iTOL-201 and is now progressing toward small animal proof of concept work to evaluate the combined technology's potential to produce ectopic livers capable of rescuing the animals from otherwise fatal liver disease without the need for immune suppression.

Key Points: 
  • The joint research collaboration has generated in vitro data with iTOL-201 and is now progressing toward small animal proof of concept work to evaluate the combined technology's potential to produce ectopic livers capable of rescuing the animals from otherwise fatal liver disease without the need for immune suppression.
  • iTolerance is an early-stage privately held regenerative medicine company developing technology to enable tissue, organoid or cell therapy without the need for life-long immunosuppression.
  • Utilizing iTOL-100 to induce local immune tolerance, iTOL-102 has the potential to be a cure for Type 1 Diabetes without the need for life-long immunosuppression.
  • LyGenesis is a clinical-stage biotechnology company whose cell therapies use patients' lymph nodes as bioreactors to regrow functioning ectopic organs.

Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022 

Retrieved on: 
Monday, May 2, 2022
CAR, Hematological Cancer Research Investment and Education Act, Cytokine, Nasdaq, Fas ligand, Chimera, Toxicity, GLOBE, CCR, Control, Cell, Safety, Gene, Neoplasm, Apoptosis, Industry, TCR, Society, TILS, Technology, Toxic shock syndrome, Therapy, Vaccine

LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the presentation of three novel cell programming approaches at the American Society of Gene & Cell Therapy (ASGCT) being held May 16-19, 2022.

Key Points: 
  • LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc(Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the presentation of three novel cell programming approaches at the American Society of Gene & Cell Therapy (ASGCT) being held May 16-19, 2022.
  • The data we are presenting showcases our industry leading T cell programming technologies, said Dr. Martin Pule, Autolus Chief Scientific Officer.
  • Co-administration with cytokines is known to boost T cell activity and persistence, but its systemic or local administration can be toxic.
  • Control systems such as this permit increased safety and control of engineered cell therapies: it makes the therapy tunable, dose dependent and reversible, and thus has applicability in a range of cell therapy approaches.

Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals

Retrieved on: 
Friday, October 15, 2021
Transfer, Death, Cell, Technology, ADS, CVR, APOP, Nasdaq, Method, B cell, Eligibility, Mergers and acquisitions, Contingent value rights, SEC, Knowledge, Deposit, CVR Partners, Computershare, Clinical trial, Patient, GLOBE, Intellectual property, Fas ligand, Income tax, U.S. Securities and Exchange Commission, Company, Forward-looking statement, Review, Sale, Regenerative medicine, American, NASDAQ, Research, Partnership, Security (finance), Fine chemical

Following the completion of the Merger, the Company will be renamed Quoin Pharmaceuticals, Ltd., and will trade on the Nasdaq Capital Market under the symbol QNRX.

Key Points: 
  • Following the completion of the Merger, the Company will be renamed Quoin Pharmaceuticals, Ltd., and will trade on the Nasdaq Capital Market under the symbol QNRX.
  • Each holder should consult with a tax advisor regarding the tax implications for such holder.
  • Cellect Biotechnology (APOP) has developed a breakthrough technology for the selection of stem cells from any given tissue that aims to improve a variety of cell-based therapies.
  • Any forward-looking statement in this press release speaks only as of the date of this press release.

Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals

Retrieved on: 
Monday, September 27, 2021
Transfer, Clinical trial, Regenerative medicine, Plan, Special, Review, Compliance, Risk, Annual report, Sale, NASDAQ, U.S. Securities and Exchange Commission, Listing Rules, Patient, APOP, Income, Corporate action, BMT, Lymphatic system, IP, Method, CA, Company, LLC, Knowledge, Listing, Agreement, Technology, Washington University in St. Louis, Research, Fas ligand, Cell, Forward-looking statement, Intellectual property, B cell, SEC, GLOBE, Pharmaceutical industry

Approximately 99% of the votes cast on the strategic merger agreement at the Special General Meeting voted in favor of approving the proposal.

Key Points: 
  • Approximately 99% of the votes cast on the strategic merger agreement at the Special General Meeting voted in favor of approving the proposal.
  • Subject to the satisfaction or waiver of all other closing conditions, the strategic merger is expected to close in October, 2021.
  • The Agreement and Plan of Merger and Reorganization has been amended by the parties therein to extend the Outside Date thereunder from September 30, 2021 to November 1, 2021.
  • Following the completion of the strategic merger, Cellect will be renamed Quoin Pharmaceuticals, Ltd., and will trade on the Nasdaq Capital Market under the symbol QNRX.

Cellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S.

Retrieved on: 
Thursday, September 2, 2021
Patient, Achievement, BMT, B cell, GVHD, Cell, Review, U.S. Securities and Exchange Commission, Leukemia, Forward-looking statement, Intellectual property, Method, Washington University in St. Louis, SEC, APOP, Lymphatic system, Company, Knowledge, Haematopoietic system, Research, Clinical trial, Technology, Professional, GLOBE, Fas ligand, NASDAQ, Regenerative medicine, Pharmaceutical industry, Fine chemical

The trial will enroll 18 patients with hematological malignancies who are undergoing a haploidentical Bone Marrow Transplantation (BMT).

Key Points: 
  • The trial will enroll 18 patients with hematological malignancies who are undergoing a haploidentical Bone Marrow Transplantation (BMT).
  • EnCellX, led by Founder and CEO Adi Mohanty, is raising funds from leading healthcare institutional investors to expedite and expand clinical development.
  • We look forward to working closely with EnCellX as its U.S. based team will work closely with Washington University to continue patient enrollment.
  • The Companys current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Cellect Biotechnology Reports Second Quarter 2021 Financial and Operating Results

Retrieved on: 
Tuesday, August 24, 2021
Company, Record, U.S. Securities and Exchange Commission, GLOBE, Regenerative medicine, SEC, Method, Knowledge, Research, Fas ligand, B cell, CPA, F4, Risk, R, APOP, Intellectual property, Cell, Forward-looking statement, CFO, American, G&A, Review, Clinical trial, NASDAQ, Mass meeting, Patient, NIS, FDA, Annual report, American depositary receipt, Technology, Security (finance), Fine chemical, Pharmaceutical industry, Coal, Lithium

Tel Aviv, Israel, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, today reported financial and operating results for the second quarter ended June 30, 2021, and provided an update on the proposed strategic merger with privately-held Quoin Pharmaceuticals and recent clinical news

Key Points: 
  • Separately, Yaron Ben-Oz, CPA, will be joining the Company as Chief Financial Officer, effective September 1, 2021.
  • General and administrative (G&A) expenses for the second quarter were $0.86 million compared to $0.65 million in the 2020 second quarter.
  • Finance expenses for the second quarter of 2021 were $0.43 million compared to finance expenses of $1.63 million in the second quarter of 2020.
  • Total comprehensive loss for the second quarter was $1.7 million, or $0.004 per share compared total comprehensive loss of $2.7 million, or $0.007 per share, in the second quarter of 2020.

The Securities and Exchange Commission Declared Cellect Biotechnology’s Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharmaceuticals

Retrieved on: 
Friday, August 13, 2021
Method, Forward-looking statement, NASDAQ, U.S. Securities and Exchange Commission, Intellectual property, Form, APOP, Clinical trial, Company, Risk, Mass meeting, GLOBE, F-4, SEC, Cell, Research, FDA, Annual report, Security (finance), Patient, Technology, Knowledge, Regenerative medicine, B cell, Review, Fas ligand, Pharmaceutical industry

Tel Aviv, Israel, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced that its registration statement filed on Form F-4 with Securities and Exchange Commission (“SEC”) on August 10, 2021 was declared effective by the SEC on August 12, 2021 (the “Form F-4”). The Form F-4 was filed in connection with the previously announced strategic merger with Quoin Pharmaceuticals, Inc., a privately held U.S. based company focused on rare and orphan diseases.

Key Points: 
  • The Form F-4 was filed in connection with the previously announcedstrategic merger with Quoin Pharmaceuticals, Inc., a privately held U.S. based company focused on rare and orphan diseases.
  • Additional information regarding the proposed strategic merger can be found in the Form F-4.
  • Cellect Biotechnology (APOP) has developed a breakthrough technology for the selection of stem cells from any given tissue that aims to improve a variety of cell-based therapies.
  • The Company's lead product is currently in FDA approved clinical trial is aimed at bone marrow transplantations in cancer treatment.